Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)
Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after
Pediatric liver transplantation. Ticagrelor (a new reversible inhibitor of P2Y12 receptor
with faster onset of action and greater platelet inhibition) was used to treat patients with
pediatric post-transplant hepatic artery thrombosis (HAT) compared to low molecular weight
heparin.